EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly

Jorge C G Blanco iD, Lori M Cullen, Arash Kamali, Fatouomata Y D Sylla, Marina S Boukhvalova, Trudy G Morrison iD

Viruses · 2023

DOI: 10.3390/v15061305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Jorge C G Blanco und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sigmovir Biosystems Inc., Rockville, MD 20850, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is a significant threat to elderly populations and repeated infections that occur throughout life are poorly protective. To assess the role of prior RSV infections as well as elderly immune senescence on vaccine efficacy, we compared immune responses after virus-like particle (VLP) immunization of elderly cotton rats and young cotton rats, both previously RSV infected, in order to mimic the human population. We show that immunization of RSV-experienced young or elderly animals resulted in the same levels of anti-pre-F IgG, anti-G IgG, neutralizing antibody titers, and protection from challenge indicating that the delivery of F and G proteins in a VLP is equally effective in activation of protective responses in both elderly and young populations. Our results suggest that F and G protein-containing VLPs induce anti-RSV memory established in prior RSV infections equally well in both young and elderly animals and thus can be an effective vaccine for the elderly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanHumansAnimalsAgedMiceAntibodies, ViralAntibodies, NeutralizingViral Fusion ProteinsSigmodontinaeImmunoglobulin GMice, Inbred BALB C

Stichwörter der Autor:innen

immunityrespiratory syncytial virusvaccinevirus-like particle

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, NeutralizingViral Fusion ProteinsImmunoglobulin G

Autor:innen und Institutionen

  • Sigmovir Biosystems Inc., Rockville, MD 20850, USA.
  • Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.

ORCID-Profile: Jorge C G Blanco, Trudy G Morrison

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Blanco, J. C. G., Cullen, L. M., Kamali, A., Sylla, F. Y. D., Boukhvalova, M. S., & Morrison, T. G. (2023). Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly. Viruses. https://doi.org/10.3390/v15061305

Vancouver

Blanco JCG, Cullen LM, Kamali A, Sylla FYD, Boukhvalova MS, Morrison TG. Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly. Viruses. 2023. doi:10.3390/v15061305

BibTeX
@article{Blanco2023,
  author = {Blanco, Jorge C G and Cullen, Lori M and Kamali, Arash and Sylla, Fatouomata Y D and Boukhvalova, Marina S and Morrison, Trudy G},
  title = {Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15061305}
}
Kostenlos starten →